Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vipul Jain

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
American Journal of Medical Genetics. Part A|March 29, 2019
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT studyDerralynn A Hughes, Kathleen Nicholls, Gere Sunder-Plassmann, et al.
Journal of Forensic and Legal Medicine|July 24, 2010
Postmortem diagnosis of acute haemorrhagic pancreatitisB Suresh Kumar Shetty, Archith Boloor, Ritesh G Menezes, et al.
Therapeutic Advances in Rare Disease|March 2, 2026
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe diseaseRobert J Hopkin, Barry J Byrne, Mazen M Dimachkie, et al.
Journal of Neurology|February 17, 2025
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Journal of Neurology|December 6, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
The Journal of Allergy and Clinical Immunology|October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studiesAna Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 4, 2026
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trialsAna Maria Giménez-Arnau, Artem Zharkov, Bin Yang, et al.
Lancet (London, England)|July 27, 2024
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsJonathan I Silverberg, Andreas Wollenberg, Adam Reich, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
American Journal of Medical Genetics. Part A|March 29, 2019
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT studyDerralynn A Hughes, Kathleen Nicholls, Gere Sunder-Plassmann, et al.
Journal of Forensic and Legal Medicine|July 24, 2010
Postmortem diagnosis of acute haemorrhagic pancreatitisB Suresh Kumar Shetty, Archith Boloor, Ritesh G Menezes, et al.
Therapeutic Advances in Rare Disease|March 2, 2026
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe diseaseRobert J Hopkin, Barry J Byrne, Mazen M Dimachkie, et al.
Journal of Neurology|February 17, 2025
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Journal of Neurology|December 6, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
The Journal of Allergy and Clinical Immunology|October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studiesAna Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 4, 2026
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trialsAna Maria Giménez-Arnau, Artem Zharkov, Bin Yang, et al.
Lancet (London, England)|July 27, 2024
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsJonathan I Silverberg, Andreas Wollenberg, Adam Reich, et al.
Pageof 4